SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes routine cGMP inspection at Cipla’s manufacturing facility in Patalganga

05 Apr 2024 Evaluate

United States Food and Drug Administration (USFDA) has concluded routine current Good Manufacturing Practices (cGMP) inspection at Cipla’s manufacturing facility located in Patalganga, Maharashtra, India from March 28, 2024 to April 4, 2024.

On conclusion of the inspection, the company has received 6 inspectional observations in Form 483. The company will work closely with the USFDA and is committed to address these comprehensively within the stipulated time. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. 


Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×